Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies
Mandate

Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies

November 10, 2009

Vinge has advised Apoteket Omstrukturering AB in connection with the reregulation of the Swedish pharmacy market and in connection with the disposal through Apoteket AB (publ) of 8 so-called cluster companies consisting of a total of 465 pharmacies to Kronans Droghandel/KF, Altor, Priveq/Investor Growth Capital and Segulah for a total purchase price of approximately SEK 5.9 billion.

The Vinge team was led by Carl Gustaf De Geer and Henrik Wenckert and included associates from different practice areas such as M&A, Banking & Finance, EU &Antitrust, IT/Telecom, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the pharmaceuticals legislation including licensing on the pharmacy market.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

 Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

 Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026